Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ruanjian Qingmai (RJQM) is a traditional Chinese medicine (TCM) formulation primarily used in the form of granules. It is derived from a classic formula developed by Professor Jiuyi Xi and has been widely used for over three decades in China to treat peripheral arterial disease (PAD), particularly cases characterized by blood vessel stasis and obstruction. The formulation has also shown efficacy in promoting wound healing, especially in diabetic ulcers, by enhancing angiogenesis and granulation tissue formation. Mechanistically, RJQM appears to act through multiple pathways including upregulation of CYP7A1 mRNA expression for lipid metabolism reprogramming, modulation of the PI3K-Akt-VEGF signaling pathway to promote vascular endothelial growth factor-mediated angiogenesis, and inhibition of inflammatory responses via the JAK2/STAT3 pathway. Clinical studies have demonstrated its benefit in improving ischemic symptoms such as intermittent claudication and increasing pain-free walking distance in PAD patients[2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ruanjian qingmai.